Anti-oxidant and anti-inflammatory mechanisms of amlodipine action to improve endothelial cell dysfunction induced by irreversibly glycated LDL

Biochemical and Biophysical Research Communications

Volumn 411, Issue 1, 2011, Pages 202-207

  Toma, Laura ^a   Stancu, Camelia S ^a   Sanda, Gabriela M ^a   Sima, Anca V ^a  

^a INSTITUTE OF CELLULAR BIOLOGY AND PATHOLOGY NICOLAE SIMIONESCU   (Romania)

Author keywords

Amlodipine; Endothelial dysfunction; Glycated LDL; NADPH oxidase; NF B; P38 MAPK

Indexed keywords

3 NITROTYROSINE; 4 HYDROXYNONENAL; AMLODIPINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCATED LOW DENSITY LIPOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LOW DENSITY LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN P22; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CELL ADHESION; DIABETES MELLITUS; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MONOCYTE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AMLODIPINE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; CALCIUM CHANNEL BLOCKERS; CHEMOKINE CCL2; ENDOTHELIAL CELLS; GENE EXPRESSION; HUMANS; LIPOPROTEINS, LDL; NADPH OXIDASE; NITRIC OXIDE SYNTHASE TYPE II; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN BIOSYNTHESIS; TRANSCRIPTION FACTOR RELA;

EID: 79960557550     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.06.137     Document Type: Article

References (33)

1. Berry C., Tardif J.C., Bourassa M.G. Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management. J. Am. Coll. Cardiol. 2007, 49:631-642.
2. Dworakowski R., Alom-Ruiz S.P., Shah A.M. NADPH oxidase-derived reactive oxygen species in the regulation of endothelial phenotype. Pharmacol. Rep. 2008, 60:21-28.
3. Lubos E., Handy D.E., Loscalzo J. Role of oxidative stress and nitric oxide in atherothrombosis. Front. Biosci. 2008, 13:5323-5344.
4. Kiyici S., Erturk E., Budak F., Ersoy C., Tuncel E., Duran C., Oral B., Sigirci D., Imamoglu S. Serum monocyte chemoattractant protein-1 and monocyte adhesion molecules in type 1 diabetic patients with nephropathy. Arch. Med. Res. 2006, 37:998-1003.
5. Klein K., Satler M., Elhenicky M., Brix J., Krzyzanowska K., Schernthaner G., Husslein P.W., Schernthaner G.H. Circulating levels of MCP-1 are increased in women with gestational diabetes. Prenat. Diagn. 2008, 28:845-851.
6. Chacon M.R., Fernandez-Real J.M., Richart C., Megia A., Gomez J.M., Miranda M., Caubet E., Pastor R., Masdevall C., Vilarrasa N., Ricard W., Vendrell J. Monocyte chemoattractant protein-1 in obesity and type 2 diabetes. Insulin sensitivity study. Obesity 2007, (Silver Spring 1):664-672.
7. Wu T., McGrath K.C., Death A.K. Cardiovascular disease in diabetic nephropathy patients: cell adhesion molecules as potential markers?. Vasc. Health Risk Manage. 2005, 1:309-316.
8. Yan S.F., Ramasamy R., Bucciarelli L.G., Wendt T., Lee L.K., Hudson B.I., Stern D.M., Lalla E., S D.U.Y., Rong L.L., Naka Y., Schmidt A.M. RAGE and its ligands: a lasting memory in diabetic complications?. Diabetes Vasc. Dis. Res. 2004, 1:10-20.
9. Tames F.J., Mackness M.I., Arrol S., Laing I., Durrington P.N. Non-enzymatic glycation of apolipoprotein B in the sera of diabetic and non-diabetic subjects. Atherosclerosis 1992, 93:237-244.
10. Sima A., Stancu C., Constantinescu E., Ologeanu L., Simionescu M. The hyperlipemic hamster - A model for testing the anti-atherogenic effect of amlodipine. J. Cell. Mol. Med. 2001, 5:153-162.
11. Yoshii T., Iwai M., Li Z., Chen R., Ide A., Fukunaga S., Oshita A., Mogi M., Higaki J., Horiuchi M. Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions. Hypertens. Res. 2006, 29:457-466.
12. Nistor A., Simionescu M. Uptake of low density lipoproteins by the hamster lung. Interactions with capillary endothelium. Am. Rev. Respir. Dis. 1986, 134:1266-1272.
13. Sima A.V., Botez G.M., Stancu C.S., Manea A., Raicu M., Simionescu M. Effect of irreversibly glycated LDL in human vascular smooth muscle cells: lipid loading, oxidative and inflammatory stress. J. Cell. Mol. Med. 2010, 14:2790-2802.
14. Fogelman A.M., Shechter I., Seager J., Hokom M., Child J.S., Edwards P.A. Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc. Natl Acad. Sci. USA 1980, 77:2214-2218.
15. Linden A., Gulden M., Martin H.J., Maser E., Seibert H. Peroxide-induced cell death and lipid peroxidation in C6 glioma cells. Toxicol. In Vitro 2008, 22:1371-1376.
16. Ungvari Z., Csiszar A., Edwards J.G., Kaminski P.M., Wolin M.S., Kaley G., Koller A. Increased superoxide production in coronary arteries in hyperhomocysteinemia: role of tumor necrosis factor-alpha, NAD(P)H oxidase, and inducible nitric oxide synthase. Arterioscler. Thromb. Vasc. Biol. 2003, 23:418-424.
17. Toma L., Stancu C.S., Botez G.M., Sima A.V., Simionescu M. Irreversibly glycated LDL induce oxidative and inflammatory state in human endothelial cells; added effect of high glucose. Biochem. Biophys. Res. Commun. 2009, 390:877-882.
18. Manduteanu I., Dragomir E., Calin M., Pirvulescu M., Gan A.M., Stan D., Simionescu M. Resist in up-regulates fractalkine expression in human endothelial cells: lack of additive effect with TNF-alpha. Biochem. Biophys. Res. Commun. 2009, 381:96-101.
19. Chrysant S.G., Lee J., Melino M., Karki S., Heyrman R. Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. J. Hum. Hypertens. 2010, 24:730-738.
20. Izzo J.L., Purkayastha D., Hall D., Hilkert R.J. Comparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension. J. Hum. Hypertens. 2010, 24:403-409.
21. Kang B.Y., Wang W., Palade P., Sharma S.G., Mehta J.L. Cardiac hypertrophy during hypercholesterolemia and its amelioration with rosuvastatin and amlodipine. J. Cardiovasc. Pharmacol. 2009, 54:327-334.
22. Lu J.C., Cui W., Zhang H.L., Liu F., Han M., Liu D.M., Yin H.N., Zhang K., Du J. Additive beneficial effects of amlodipine and atorvastatin in reversing advanced cardiac hypertrophy in elderly spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol. 2009, 36:1110-1119.
23. Takai S., Jin D., Sakonjo H., Miyazaki M. Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats. Hypertens. Res. 2010, 33:953-959.
24. Szabo C. Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction. Br. J. Pharmacol. 2009, 156:713-727.
25. Mason R.P., Kubant R., Heeba G., Jacob R.F., Day C.A., Medlin Y.S., Funovics P., Malinski T. Synergistic effect of amlodipine and atorvastatin in reversing LDL-induced endothelial dysfunction. Pharm. Res. 2008, 25:1798-1806.
26. Pandolfi A., De Filippis E.A. Chronic hyperglicemia and nitric oxide bioavailability play a pivotal role in pro-atherogenic vascular modifications. Genes Nutr. 2007, 2:195-208.
27. Mawatari E., Hongo M., Sakai A., Terasawa F., Takahashi M., Yazaki Y., Kinoshita O., Ikeda U. Amlodipine prevents monocrotaline-induced pulmonary arterial hypertension and prolongs survival in rats independent of blood pressure lowering. Clin. Exp. Pharmacol. Physiol. 2007, 34:594-600.
28. Libby P., Ridker P.M., Hansson G.K. Inflammation in atherosclerosis: from pathophysiology to practice. J. Am. Coll. Cardiol. 2009, 54:2129-2138.
29. Chen X.L., Zhang Q., Zhao R., Medford R.M. Superoxide, H2O2, and iron are required for TNF-alpha-induced MCP-1 gene expression in endothelial cells: role of Rac1 and NADPH oxidase. Am. J. Physiol. Heart Circ. Physiol. 2004, 286:H1001-1007.
30. Yu T., Morita I., Shimokado K., Iwai T., Yoshida M. Amlodipine modulates THP-1 cell adhesion to vascular endothelium via inhibition of protein kinase C signal transduction. Hypertension 2003, 42:329-334.
31. Rosenkranz A.C., Lob H., Breitenbach T., Berkels R., Roesen R. Endothelial antioxidant actions of dihydropyridines and angiotensin converting enzyme inhibitors. Eur. J. Pharmacol. 2006, 529:55-62.
32. Mason R.P., Marche P., Hintze T.H. Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler. Thromb. Vasc. Biol. 2003, 23:2155-2163.
33. Batova S., DeWever J., Godfraind T., Balligand J.L., Dessy C., Feron O. The calcium channel blocker amlodipine promotes the unclamping of eNOS from caveolin in endothelial cells. Cardiovasc. Res. 2006, 71:478-485.